Precision Cancer Therapies, Immunologic Approaches for the Treatment of Lymphoid Malignancies

Owen A. O'Connor , Stephen M. Ansell , John G. Gribben 지음

Wiley-Blackwell 2024년 02월 21일 출간

작품소개

책소개

Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science. Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T). Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also: Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biology Focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms Covers FDA-approved drugs and their indications, as well as drugs currently in development Provides information on mon

목차

List of Contributors xix Volume Foreword xxiv Volume Preface xxvi Series Preface xxviii Section I Historical Perspective 1 1 The Distinguished History of Immunotherapy Development in Cancer 3Stephen M. Ansell Section II Targeting Cell Surface Receptors 9 2 Development of Monoclonal Antibodies for the Treatment of Lymphoma: Setting the Stage 11George J. Weiner 3 Pharmacology to Practice: The Similarities and Differences of Drugs Targeting CD20 22Jennifer K. Lue and Bruce D. Cheson 4 Pharmacology to Practice: Targeting CD19 and 22 40Nilanjan Ghosh and Sonali M. Smith 5 Targeting Other Promising Cell Surface Receptors: ROR1, CD38, CD25, and CCR4 52Michael Wang Section III Antibody Drug Conjugates (ADC) 73 6 Principles of Antibody Drug Development 75Eric L. Sievers 7 Targeting CD30 in Lymphoid Neoplasms 87Barbara Pro 8 Targeting CD79b in B-cell Malignancies 100Colette Owens and Gilles Salles 9 Radioimmunotherapy: Is There Any Future Role? 108Alessandro Broccoli and Pier Luigi Zinzani Section IV Targeting Immune Checkpoint 123 10 The Biology of Immune Checkpoint Blockade 125Timothy N. Bullock 11 Mechanism of Action and Pharmacologic Features of Drugs Targeting PD-1/PDL-1 and CTLA-4 139Marc-Anthony Rodriguez, Ryan Bucktrout, Andrea Orlando, Inna Serganova, and Roberta Zappasodi 12 Other Immune Checkpoint Targets of Interest 156Clifford M. Csizmar and Stephen M. Ansell 13 Clinical Experiences with Immune Checkpoint Inhibitors in Lymphomas 190John M. Timmerman Section V Targeting Macrophages and SIRP-α Disrupting the "Do Not Eat Me" 209 14 The Role of CD47 in Lymphoma Biology and Strategies for Therapeutic Targeting 2

출판사 서평

작가정보

저자(글) Owen A. O'Connor

저자(글) Stephen M. Ansell

저자(글) John G. Gribben